EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

Liver Cancer Summit 2022

 

3-4 February 2022
Close
N. Poster
Poster title
Applicant name
Status
  PO-004 Texture analysis using computed tomography data may be helpful for the risk stratification of clinical significant portal hypertension in patients with liver cirrhosis Shang Wan Received Received
  PO-005 Quantitative parameters of esophageal varices based on computed tomography may be used for predicting severe varices in patients with liver cirrhosis Shang Wan Received Received
  PH-017 Mixed HCC-CCA originates from hepatic progenitor cells, is dependent on IL6 signaling and is ablated by senolytic agents nofar rosenberg Received Received
  PO-022 Hepatocellular carcinoma is associated with an increased prevalence of metabolic syndrome after liver transplantation Asahi Hoque Received Received
  PO-024 Occult hepatitis B virus infection and hepatocellular carcinoma occurrence after hepatitis C virus eradication: the silent enemy Cristina Muzica Received Received
  PH-025 A new 3D Slicer plug-in for the interactive annotation and segmentation of liver anatomy Antoine Vacavant Received Received
  PO-028 Mathematical modeling of cancer cells and vasculature dynamics with serological and imaging biomarkers suggests synergistic effects of TACE and TKIs in HCC patients Francesco Damone Received Received
  PH-029 Independent validation of a glycomics-based test associated with risk of HCC development in cirrhosis: a new tool for screening optimisation? Verhelst Xavier Received Received
  PH-030 Pretransplant changes in serum protein glycosylation are associated to risk of HCC recurrence after liver transplantation and provide a potential prognostic biomarker: a proof-of-concept study Verhelst Xavier Received Received
  PH-038 Circulating tumor DNA methylation markers for diagnosis of liver cancer: A multicenter diagnostic trial Maomao Cao Received Received
  PO-047 The clinical experience with stereotactic ablative radiotherapy for hepatocellular carcinoma in a tertiary referral center: a case series Sjoerd Spijkerboer Received Received
  PH-058 The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma. Claudia Fulgenzi Received Received
  PO-064 Gut bacteria modulate anti-tumour immunity in patients with Hepatocellular Carcinoma Dhruti Devshi Received Received
  PO-068 Hepatocellular carcinoma alters granulopoiesis to produce neutrophils with an immature phenotype Daniel Geh Received Received
  PH-073 Tumor intrinsic and extrinsic role of Axl in models of hepatocellular carcinoma Kristina Breitenecker Received Received
  PH-076 Transarterial chemoembolization for hepatocellular carcinoma in clinical practice: temporal trends and survival outcomes over the last three decades in Italy Filippo Pelizzaro Received Received
  BP-094 PRAME is a novel target of Axl signaling in hepatocellular carcinoma progression Viola Hedrich Received Received
  PH-098 Effect of liver stiffness on hepatocellular carcinoma phenotype in a biomimetic 3D model Jaafar Khaled Received Received
  PO-102 Inhibiting IRE1-a endonuclease activity potentiates the effect of doxorubicin in hepatocellular carcinoma. MARIA KOPSIDA Received Received
  PO-107 Ouctome of hydrodissection radiofrequency ablation in patients with pericholecystic hepatocellular carcinoma Benedetta Stefanini Received Received
  PO-119 Efficacy of combination therapy with lenvatinib, programmed cell death 1 inhibitors and transarterial therapy: a propensity score-matching cohort study Wei Lu Received Received
  BP-120 Hepatocellular carcinoma tumor burden in the GAN diet-induced obese mouse model of NASH with advanced fibrosis Michael Feigh Received Received
  BP-122 Unrecognized liver cirrhosis: common and associated with worse survival in patients diagnosed with hepatocellular carcinoma a Swedish nationwide cohort study Juan Vaz Received Received
  PO-126 Novel platinum-based chemotherapeutic agents halt cholangiocarcinoma progression through the induction of inter-strand DNA breaks, preventing DNA repair mechanisms Irene Olaizola Received Received
  PH-127 Fatty acid oxidation fuels the progression of highly proliferative cholangiocarcinoma cells Mikel Ruiz de Gauna Received Received
  PH-128 Progression patterns and therapeutic sequencing following immune checkpoint inhibition for HCC: an observational study. David J Pinato Received Received
  PO-129 Clinicopathological and survival features of hepatic lymphomas: a retrospective single-center study Emanuel Dias Received Received
  PO-132 Enhanced recovery after surgery: application of 2016 liver surgery guidelines in a middle volume western center Alessandro Fogliati Received Received
  PO-135 Prominent pseudoacini in focal nodular hyperplasia: a potential diagnostic pitfall Donghai Wang Received Received
  PO-141 Investigating CXCR2 inhibition anti-PD1 immunotherapy in a NASH-HCC mouse model using Imaging Mass Cytometry Erik Ramon Gil Received Received
  PO-143 Hepatocellular carcinoma recurrence post Liver transplant Yaqza Hussain Received Received
  PO-148 Systemic treatments with tyrosine kinase inhibitors and platinum-based chemotherapy in patients with unresectable or metastatic hepato-cholangiocarcinoma Elia Gigante Received Received
  PO-150 Involvement of E2F2-miR34a-5p axis in the metabolic dysregulation of MAFLD-related HCC Maider Apodaka Biguri Received Received
  PO-154 Association between metabolic disorders and biliary tract cancer: impact of an emergent risk factor in a real-world cohort. Leonardo da Fonseca Received Received
  PO-159 Epidemiology of hepatocellular carcinoma in Portugal Mario Jorge Silva Received Received
  PO-160 CXCR2 inhibition sensitises to anti-PD1 therapy in NASH-HCC jack leslie Received Received
  PH-161 Opposite roles for PD-1 expressing tissue resident and exhausted T cells in Hepatocellular Carcinoma Maryam Barsch Received Received
  PO-163 The NADPH oxidase NOX4 regulates redox and metabolic homeostasis in hepatocellular carcinoma Irene Peñuelas Received Received
  PO-170 P53 and VEGF immunoexpression are predictive biomarkers of Sorafenib efficacy in an experimental model of NASH-related HCC João Pedro Nassar Reis Received Received
  PO-175 A retrospective real-world study of transarterial gemcitabine-based chemoembolization plus lenvatinib with or without a PD-1 inhibitor for unresectable intrahepatic cholangiocarcinoma ya li Received Received
  PO-176 Factors associated with the radiological response of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma Yuka Hayakawa Received Received
  PH-177 Cholangiocarcinoma-on-chip: a 3D liver tumor model michela polidoro Received Received
  PO-179 Altered glutamine metabolism in intrahepatic cholangiocarcinoma: biological effects of glutaminase inhibitor michela polidoro Received Received
  PH-181 The development of ex vivo human models of hepatocellular carcinoma in precision cut liver slices for high throughput screening of anti-cancer therapies Amy Collins Received Received
  PO-190 Role of ABC drug efflux pumps in the resistance of hepatoblastoma to conventional chemotherapy Candela Cives-Losada Received Received
  PO-193 MiR-30e-3p plays a dual role in hepatocellular carcinoma and predicts sorafenib resistance Ilaria Leoni Received Received
  PH-195 Usefulness of serum metabolomic profiling for the differential diagnosis in liver cancer: a validation study Rocio IR Macias Received Received
  PO-202 Direct and indirect antitumoral effects of cold atmospheric plasma : a disruptive technological approach for the local treatment of cholangiocarcinoma Allan Pavy Received Received
  PO-203 The probability to be cured after surgery for hepatocellular carcinoma: can these patients reach again the general population life span? A national multicentric epidemiologic study Simone Famularo Received Received
  PO-211 Stratification of cirrhosis etiologies identifies novel immune biomarkers for early stage hepatocellular carcinoma Boris Beudeker Received Received
  PO-221 Liver biopsy biomarkers in a phase 1 study of the prodrug MIV-818 demonstrates proof-of-concept for cancer in the liver Fredrik Oberg Received Received
  PO-224 Notch signalling is significantly altered in KPPTom mice, a bespoke murine model of intrahepatic cholangiocarcinoma Anabel Martinez Lyons Received Received
  PO-225 BH3 mimetics for precision prevention for beta-catenin mutant hepatocellular carcinoma Stephanie May Received Received
  PO-231 Early Kupffer cell depletion does not affect hepatocellular carcinoma progression in mice Bart Vanderborght Received Received
  PO-235 Disease positioning identifies distinct hepatocellular carcinoma subtypes within genetically engineered mouse models which transcriptionally relate to equivalent subclasses in human hepatocellular carcinoma Miryam Mller Received Received
  PH-241 ZEB1 expression mediates chemoresistance in cholangiocarcinoma by disrupting the pro/anti-apoptotic balance in stromal myofibroblasts Javier Vaquero Received Received
  PO-259 Response to sorafenib in HCC is mediated by hypoxia-related proteins and induces distinct immune-related signatures Jovana Hajduk Received Received
  PH-264 Benefits of tailored HCC surveillance programs on case-fatality rate and cancer-specific mortality using a modelling approach Massih Ningarhari Received Received
  PO-266 Proteomic profiling for theranostic approches in Hepatocellular Carcinoma Anne-Aurélie RAYMOND Received Received
  PO-267 Comparative in vitro evaluation of cancer therapies in various hepatocellular carcinoma experimental models Loraine Cabral Received Received
  PO-272 Senescence-specific adaptive immune response to oncogene-induced-senescence (OIS) within the murine liver Sarah Gough Received Received
  PO-280 Transcriptomic profiling of primary sclerosing cholangitis associated cholangiocarcinoma identifies novel genes of interest Megan Illingworth Received Received
  PO-284 Predictors of survival of patients with hepatocellular carcinoma in best supportive care Claudia Campani Received Received
  PO-286 Characterization of Transforming Growth Factor (TGF)-beta signalling in sorafenib-resistant hepatocarcinoma cell lines. Ester Gonzalez-Sanchez Received Received
  PO-287 PD1 T-cells correlate with Nerve Fiber Density as a prognostic biomarker in patients with resected perihilar cholangiocarcinoma. Lara Heij Received Received
  PO-288 Targeting of nuclear receptors and microRNA-21 ameliorates non-alcoholic fatty liver disease progression towards carcinogenesis in mice André L. Simao Received Received
  PH-289 Lipid droplets are mechanical stresses in non-alcoholic fatty liver disease Abigail Loneker Received Received
  PO-290 SerpinB3/4 expression is associated with poor prognosis in patients with cholangiocarcinoma Andrea Martini Received Received
  PH-293 Anticancer activity of novel vicinal diaryl isoxazole compounds in hepatocellular carcinoma Esra Nalbat Received Received
  PH-295 Serum IL-8 is associated with altered neutrophil phenotype and poorer survival in patients with hepatocellular carcinoma Helen Louise Reeves Received Received
  PO-296 In vitro effects of magnetic hyperthermia via a nanomodified polymer stent for cholangiocarcinoma treatment Anjali A. Roth Received Received
  PO-300 Genes modulating liver fat accumulation and lipogenesis predict development of hepatocellular carcinoma among direct antiviral agents treated cirrhotics C with and without viral clearance Antonio Acquaviva Received Received
  PO-302 Comparison of therapeutic outcomes of liver resection and transarterial chemoembolization in multifocal HCC: a propensity score-matched analysis Claudia Campani Received Received
  PO-306 Modulation of the cholangiocarcinoma stem-like compartment by monounsaturated fatty acids Giulia Lori Received Received
  PO-307 Potential role of soluble triggering receptor expressed on myeloid cells 2 in risk stratification of patients with hepatocellular carcinoma Francesca Baorda Received Received
  BP-308 Liver transplantation for combined hepatocellular-cholangiocarcinoma: An analysis of the European Liver Transplant Registry Marco Claasen Received Received
  PO-309 Cross-talk between MerTK-expressing stromal cells and cholangiocarcinoma Mirella Pastore Received Received
  PO-312 Performance of Toronto HCC risk index and aMAP score in predicting HCC development in patient with cirrhosis Nouha Trad Received Received
  PO-313 Liver transplantation for fibrolamellar hepatocellular carcinoma: An analysis of the European Liver Transplant Registry Marco Claasen Received Received
  PO-314 Performance of ten non-invasive liver function tests in predicting hepatocellular carcinoma development in patients with cirrhosis Nouha Trad Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Cristina Miralles
Hours: Mon-Fri 8:30-15:00
20:02
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

Liver Cancer Summit 2022

 

3-4 February 2022
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 03/02/2022 TO 03/02/2023
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                  




PosterSessionOnline
Logo Draft
 
Logo Cert